<DOC>
	<DOCNO>NCT01754142</DOCNO>
	<brief_summary>The purpose post-marketing surveillance investigate confirm type incidence newly identify adverse event factor affect safety efficacy Kombiglyze Extended release ( XR ) regulatory authority manage marketing approval properly</brief_summary>
	<brief_title>Korean Post-marketing Surveillance Kombiglyze XR®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . ≥ 18 year age Have diagnose Type 2 diabetes mellitus ( T2DM ) Are initiate Kombiglyze XR treatment within approved Korean indication Being treat indication approve use Kombiglyze XR Korea Is contraindicate use Kombiglyze XR describe Korean label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>